AstraZeneca rose over 2% in morning trading on positive late-stage data for breast cancer therapy.
The Anglo-Swedish drugmaker has partnered with Daiichi Sankyo(OTCPK:DSKYF)(OTCPK:DSNKY)to design Enhertu as an antibody-drug conjugate (ADC) targeted at HER2, a tyrosine kinase receptor expressed on multiple types of cancer.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments